Share chart Intra-Cellular Therapies, Inc.
Extended chart
Simple chart
About
Intra-Cellular Therapies, Inc., биофармацевтическая компания, разрабатывает новые препараты для лечения психоневрологических и неврологических заболеваний и других заболеваний центральной нервной системы (ЦНС) в США. Компания разрабатывает свой ведущий кандидат на лекарство CAPLYTA для лечения шизофрении, биполярного расстройства, поведенческих нарушений, связанных с деменцией, аутизмом и другими заболеваниями ЦНС. more details| IPO date | 2014-01-07 |
|---|---|
| ISIN | US46116X1019 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.intracellulartherapies.com |
| Цена ао | 94.87 |
| Change price per day: | 0% (94.87) |
|---|---|
| Change price per week: | +16.01% (81.78) |
| Change price per month: | +13.75% (83.4) |
| Change price per 3 month: | +28.48% (73.84) |
| Change price per half year: | +24% (76.51) |
| Change price per year: | +42.96% (66.36) |
| Change price per 3 year: | +86.13% (50.97) |
| Change price per 5 year: | +527.86% (15.11) |
| Change price per 10 year: | 0% (94.87) |
| Change price per year to date: | +12.75% (84.14) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
|---|---|---|---|---|---|---|---|---|---|
| 23.08.2024 | 23.08.2024 | Mates Sharon Officer |
Purchase | 74.4 | 2 133 790 | 28680 | 0 | 0.04 | link |
| 24.06.2024 | 25.06.2024 | RIGGS RORY B Director |
Sale | 75.57 | 337 193 | 4462 | 0 | -0.01 | link |
| 24.06.2024 | 25.06.2024 | RIGGS RORY B Director |
Purchase | 16.86 | 337 200 | 20000 | 0 | 0.02 | link |
| 26.02.2024 | 27.02.2024 | Durgam Suresh K. EVP, Chief Medical Officer |
Sale | 70.17 | 288 539 | 4112 | 0 | -0.01 | link |
| 26.02.2024 | 27.02.2024 | Hineline Lawrence J. SVP of Finance, CFO |
Sale | 69.43 | 925 988 | 13337 | 0 | -0.02 | link |
| 26.02.2024 | 27.02.2024 | Hineline Lawrence J. SVP of Finance, CFO |
Purchase | 36.89 | 216 987 | 5882 | 0 | 0.01 | link |
| 26.02.2024 | 27.02.2024 | Halstead Michael EVP and General Counsel |
Sale | 69.53 | 549 774 | 7907 | 0 | -0.01 | link |
| 11.01.2024 | 12.01.2024 | Halstead Michael EVP and General Counsel |
Sale | 66.83 | 3 341 500 | 50000 | 0 | -0.06 | link |
| 11.01.2024 | 12.01.2024 | Halstead Michael EVP and General Counsel |
Purchase | 13.6 | 680 000 | 50000 | 0 | 0.06 | link |
| 28.03.2023 | 30.03.2023 | Neumann Mark EVP, Chief Commercial Officer |
Sale | 54.31 | 847 453 | 15604 | 0 | -0.02 | link |
| 13.03.2023 | 13.03.2023 | Mates Sharon Chairman, President & CEO |
Sale | 44.99 | 925 219 | 20565 | 0 | -0.03 | link |
| 13.03.2023 | 13.03.2023 | Mates Sharon Chairman, President & CEO |
Purchase | 3.26 | 65 200 | 20000 | 0 | 0.02 | link |
| 13.03.2023 | 13.03.2023 | Hineline Lawrence J. SVP of Finance CFO |
Sale | 44.93 | 250 799 | 5582 | 0 | -0.01 | link |
| 13.03.2023 | 13.03.2023 | Halstead Michael EVP and General Counsel |
Sale | 44.94 | 330 039 | 7344 | 0 | -0.01 | link |
| 13.03.2023 | 13.03.2023 | Neumann Mark EVP, Chief Commercial Officer |
Sale | 44.98 | 169 035 | 3758 | 0 | 0 | link |
| 13.03.2023 | 13.03.2023 | Durgam Suresh K. EVP, Chief Medical Officer |
Sale | 45.04 | 330 774 | 7344 | 0 | -0.01 | link |
| 10.03.2023 | 13.03.2023 | Mates Sharon Chairman, President & CEO |
Sale | 43.15 | 1 802 380 | 41770 | 0 | -0.05 | link |
| 10.03.2023 | 13.03.2023 | Hineline Lawrence J. SVP of Finance CFO |
Sale | 43.06 | 674 449 | 15663 | 0 | -0.02 | link |
| 10.03.2023 | 13.03.2023 | Halstead Michael EVP and General Counsel |
Sale | 43.1 | 720 115 | 16708 | 0 | -0.02 | link |
| 10.03.2023 | 13.03.2023 | Neumann Mark EVP, Chief Commercial Officer |
Sale | 43.34 | 370 557 | 8550 | 0 | -0.01 | link |
| 21.09.2022 | 23.09.2022 | Hineline Lawrence J. SVP of Finance CFO |
Sale | 45.63 | 2 973 430 | 65164 | 0 | -0.08 | link |
| 21.09.2022 | 23.09.2022 | Hineline Lawrence J. SVP of Finance CFO |
Purchase | 15.47 | 1 008 090 | 65164 | 0 | 0.08 | link |
| 04.03.2022 | 04.03.2022 | Durgam Suresh K. Chief Medical Officer |
Sale | 55.52 | 214 307 | 3860 | 0 | 0 | link |
| 02.03.2022 | 04.03.2022 | Durgam Suresh K. Chief Medical Officer |
Sale | 56.98 | 238 005 | 4177 | 0 | -0.01 | link |
| Institutions | Volume | Share, % |
|---|---|---|
| FMR, LLC | 11457694 | 11.84 |
| Vanguard Group Inc | 9094302 | 9.39 |
| Blackrock Inc. | 8193544 | 8.46 |
| Wasatch Advisors LP | 3627308 | 3.75 |
| Bellevue Group AG | 3066400 | 3.17 |
| Avoro Capital Advisors LLC | 2255555 | 2.33 |
| State Street Corporation | 2220850 | 2.29 |
| JP Morgan Chase & Company | 2072615 | 2.14 |
| Geode Capital Management, LLC | 2001791 | 2.07 |
| Deep Track Capital, LP | 2000000 | 2.07 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Michael I. Halstead J.D. | President | 983.65k | 1973 (52 years) |
| Dr. Suresh K. Durgam M.D. | Executive VP & Chief Medical Officer | 961.84k | 1969 (56 years) |
| Mr. Mark Neumann | EVP & Chief Commercial Officer | 998.36k | 1963 (62 years) |
| Mr. Juan Fernando Sanchez | Vice President of Corporate Communications & Investor Relations | 296.75k | 1971 (54 years) |
| Ms. Karen Patruno Sheehy Esq. | Senior VP & Chief Compliance Officer | N/A | 1962 (63 years) |
| Dr. Michael Olchaskey | Senior VP & Head of Regulatory Affairs | N/A | |
| Mr. John A. Bardi | Senior VP of Market Access, Policy & Government Affairs | N/A | |
| Dr. Robert E. Davis Ph.D. | Senior VP & Chief Scientific Officer | 646.12k | 1951 (74 years) |
| Dr. Sharon Mates Ph.D. | Co-Founder, Chairman & CEO | 2.23M | 1953 (72 years) |
| John P. Condon | Senior Vice President, General Counsel & Secretary |
Address: United States, New York, NY , 430 East 29th Street - open in Google maps, open in Yandex maps
Website: https://www.intracellulartherapies.com
Website: https://www.intracellulartherapies.com
